Ticagrelor for the treatment of acute coronary syndromes

unless specifically contraindicated. Following an initial loading dose of aspirin, the maintenance dose is 75 to 150 mg per day. 2.3 Ticagrelor is contraindicated in patients with active pathological bleeding, a history of intracranial haemorrhage, or moderate-to-severe hepatic impairment. Co-administration of ticagrelor with a strong CYP3A4 inhibitor (for example, ketoconazole, clarithromycin, nefazodone, ritonavir, or atazanavir) is also contraindicated. The most commonly reported adverse reactions to treatment with ticagrelor include dyspnoea, epistaxis, gastrointestinal haemorrhage, subcutaneous or dermal bleeding, and bruising. For full details of adverse effects and contraindications, see the SPC. 2.4 The manufacturer stated in its submission that the cost of 90 mg tablets of ticagrelor is Â£54.60 for a pack of 56 tablets (28 days). Costs may vary in different settings because of procurement discounts. 3 The manufacturer's submission The Appraisal Committee considered evidence submitted by the manufacturer of ticagrelor and a review of this submission by the Evidence Review Group (ERG). This evidence related to the clinical and cost effectiveness of ticagrelor plus aspirin. Clinical effectiveness 3.1 For the comparison of ticagrelor plus aspirin with clopidogrel plus aspirin, the manufacturer identified 1 trial, the PLATO trial, an international, multicentre, randomised, double-blind, double-dummy, parallel group, phase 3 study. The
